Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ABHIJIT A RAVAL

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1508052275
CMS profile
249832
Location
ANDERSON, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$186,676.93

220 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ABHIJIT A RAVAL

NPI 1508052275 · CMS profile ID 249832

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

ANDERSON, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508052275?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ABHIJIT A RAVAL, NPI 1508052275, CMS profile ID 249832. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508052275?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ABHIJIT A RAVAL, NPI 1508052275, CMS profile ID 249832. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508052275?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ABHIJIT A RAVAL, NPI 1508052275, CMS profile ID 249832, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 220 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1508052275?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

220 matching records · $186,676.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 220 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 220.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Mylan Specialty L.P. $30.0010/27/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751385787 CMS
Mylan Specialty L.P. $271.8810/27/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751385789 CMS
Mylan Specialty L.P. $870.0010/27/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751386141 CMS
Mylan Specialty L.P. $1,305.0010/27/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751409135 CMS
Actelion Pharmaceuticals US, Inc. $16.1910/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718930277 CMS
Mylan Specialty L.P. $29.0310/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751385997 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.3710/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720944729 CMS
Mylan Specialty L.P. $110.1010/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751388557 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.3010/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720944735 CMS
Insmed, Inc. $1,125.0010/20/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739691361 CMS
Insmed, Inc. $14.1610/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739690675 CMS
Mylan Specialty L.P. $125.0010/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751409131 CMS
GlaxoSmithKline, LLC. $3,600.0010/13/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738745483 CMS
AstraZeneca Pharmaceuticals LP $11.5610/12/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735796853 CMS
GlaxoSmithKline, LLC. $3,600.0010/06/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738725987 CMS
GlaxoSmithKline, LLC. $3,600.0010/06/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738898175 CMS
Actelion Pharmaceuticals US, Inc. $1,010.0010/02/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718930379 CMS
Insmed, Inc. $4.8110/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739694283 CMS
Mylan Specialty L.P. $33.1210/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751385695 CMS
Mylan Specialty L.P. $115.4310/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751409149 CMS
Mylan Specialty L.P. $33.0709/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751385705 CMS
United Therapeutics Corporation $53.8709/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752465763 CMS
Actelion Pharmaceuticals US, Inc. $1,010.0009/24/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718930373 CMS
GlaxoSmithKline, LLC. $79.1109/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738671665 CMS
GlaxoSmithKline, LLC. $3,600.0009/22/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738634481 CMS
Bayer HealthCare Pharmaceuticals Inc. $397.0009/17/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713649755 CMS
GlaxoSmithKline, LLC. $28.4009/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738546065 CMS
Actelion Pharmaceuticals US, Inc. $1,010.0009/11/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718930365 CMS
United Therapeutics Corporation $2,380.0009/11/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752465371 CMS
Bayer HealthCare Pharmaceuticals Inc. $2,128.5009/10/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713632975 CMS
Insmed, Inc. $6.8209/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739688307 CMS
AstraZeneca Pharmaceuticals LP $900.0009/01/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736337197 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $610.0009/01/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720944823 CMS
GlaxoSmithKline, LLC. $3,600.0009/01/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738801585 CMS
Mylan Specialty L.P. $1,087.5008/27/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751385263 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $610.0008/25/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720944725 CMS
GlaxoSmithKline, LLC. $3,600.0008/25/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738863251 CMS
Actelion Pharmaceuticals US, Inc. $760.0008/21/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718930273 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,015.0008/18/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720944809 CMS
GlaxoSmithKline, LLC. $1,200.0008/18/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738714045 CMS
United Therapeutics Corporation $15.6908/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752464897 CMS
Bayer HealthCare Pharmaceuticals Inc. $1,324.0008/17/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713647897 CMS
United Therapeutics Corporation $18.7708/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752464877 CMS
Actelion Pharmaceuticals US, Inc. $1,010.0008/13/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718930357 CMS
Actelion Pharmaceuticals US, Inc. $1,010.0008/13/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718930359 CMS
GlaxoSmithKline, LLC. $12.8408/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738867161 CMS
Insmed, Inc. $450.0008/04/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739694893 CMS
GlaxoSmithKline, LLC. $1,800.0007/28/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738547333 CMS
United Therapeutics Corporation $1,270.0007/23/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752464511 CMS
GlaxoSmithKline, LLC. $3,600.0007/21/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738652299 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $254,510.06 377
PY2020 $186,676.93 220
PY2021 $216,097.92 179
PY2022 $254,503.97 206
PY2023 $312,204.72 321
PY2024 $330,812.03 349
PY2025 $422,797.33 347

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $214,139.04 41
PY2024 Principal investigator $193,368.66 61
PY2023 Principal investigator $238,589.50 109
PY2022 Principal investigator $258,495.76 73
PY2021 Principal investigator $83,765.21 26
PY2020 Principal investigator $20,284.58 15
PY2019 Principal investigator $41,019.00 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Mannkind Corporation $1,000.00 12/24/2025 Covered Recipient Teaching Hospital
ANMED HEALTH
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250897770
Principal investigator 1 SANOFI US SERVICES INC. $13,229.00 12/04/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype No dispute reported 06/30/2026 1226142167
Principal investigator 1 Janssen Research & Development, LLC $400.00 12/01/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175388505
Principal investigator 1 United Therapeutics Corporation $1,565.00 12/01/2025 Covered Recipient Teaching Hospital
Anmed Health
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242380240
Principal investigator 1 United Therapeutics Corporation $4,587.50 11/12/2025 Covered Recipient Teaching Hospital
Anmed Health
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242380242
Principal investigator 1 Gyrus ACMI, Inc. $5,143.75 11/04/2025 Covered Recipient Teaching Hospital
Anmed Health
The Spiration Valve System (SVS) Post-Market Registry Study for Severe Emphysema No dispute reported 06/30/2026 1186243340
Principal investigator 1 Janssen Research & Development, LLC $978.00 10/30/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175388534
Principal investigator 1 United Therapeutics Corporation $2,175.00 10/17/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380210
Principal investigator 1 United Therapeutics Corporation $3,500.00 10/17/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380216
Principal investigator 1 United Therapeutics Corporation $7,005.00 10/17/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380222
Principal investigator 1 United Therapeutics Corporation $21,510.00 10/17/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380234
Principal investigator 1 Gyrus ACMI, Inc. $6,406.25 10/15/2025 Covered Recipient Teaching Hospital
Anmed Health
The Spiration Valve System (SVS) Post-Market Registry Study for Severe Emphysema No dispute reported 06/30/2026 1186243338
Principal investigator 1 Insmed, Inc. $2,763.96 10/15/2025 Covered Recipient Teaching Hospital
Anmed Health
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650080
Principal investigator 1 United Therapeutics Corporation $10,222.95 10/06/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380228
Principal investigator 1 Mannkind Corporation $6,000.00 08/29/2025 Covered Recipient Teaching Hospital
ANMED HEALTH
ICON-1 PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF TREATMENT WITH MNKD-101, CLOFAZAMINE INHALATION SUSPENSION No dispute reported 06/30/2026 1250897768
Principal investigator 1 United Therapeutics Corporation $442.50 08/06/2025 Covered Recipient Teaching Hospital
Anmed Health
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242380238
Principal investigator 1 United Therapeutics Corporation $480.00 07/31/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380204
Principal investigator 1 United Therapeutics Corporation $93.75 07/18/2025 Covered Recipient Teaching Hospital
Anmed Health
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242380236
Principal investigator 1 United Therapeutics Corporation $400.00 07/15/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380202
Principal investigator 1 United Therapeutics Corporation $870.00 07/04/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380208
Principal investigator 1 United Therapeutics Corporation $3,500.00 07/04/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380214
Principal investigator 1 United Therapeutics Corporation $5,604.00 07/04/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380218
Principal investigator 1 United Therapeutics Corporation $9,775.30 07/04/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380224
Principal investigator 1 United Therapeutics Corporation $12,906.00 07/04/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380230
Principal investigator 1 Janssen Research & Development, LLC $200.00 06/26/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175388510
Principal investigator 1 Janssen Research & Development, LLC $1,078.00 05/26/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175388528
Principal investigator 1 Insmed, Inc. $1,000.00 05/02/2025 Covered Recipient Teaching Hospital
Anmed Health
A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects With Newly Diagnosed Nontuberculous Mycobact No dispute reported 06/30/2026 1189650078
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,768.75 04/28/2025 Non-covered Recipient Entity
Anmed Health
BAY 632521, RiOciguAt UseRs Registry The ROAR registry No dispute reported 06/30/2026 1225419815
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,025.92 04/10/2025 Non-covered Recipient Entity
Anmed Health
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1235999001
Principal investigator 1 United Therapeutics Corporation $9,705.00 04/09/2025 Covered Recipient Teaching Hospital
Anmed Health
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242380246
Principal investigator 1 United Therapeutics Corporation $3,407.65 04/04/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380212
Principal investigator 1 United Therapeutics Corporation $400.00 03/13/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380200
Principal investigator 1 United Therapeutics Corporation $5,741.00 03/05/2025 Covered Recipient Teaching Hospital
Anmed Health
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242380244
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $31,114.00 02/12/2025 Covered Recipient Teaching Hospital
Anmed Health
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1236001835
Principal investigator 1 United Therapeutics Corporation $400.00 02/07/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380198
Principal investigator 1 Janssen Research & Development, LLC $300.00 01/27/2025 Covered Recipient Teaching Hospital
Anmed Health
A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adaptive Event driven Study to Compare Efficacy Safety and Tolerability of Macitentan 75 mg Versus Macitentan 10 mg in Patients with Pulmonary Arterial Hypertension Followed by an Open label Treatment Period With Macitentan 75 mg. No dispute reported 06/30/2026 1175388538
Principal investigator 1 United Therapeutics Corporation $870.00 01/22/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380206
Principal investigator 1 United Therapeutics Corporation $7,005.00 01/22/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380220
Principal investigator 1 United Therapeutics Corporation $17,208.00 01/22/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380232
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,134.81 01/21/2025 Non-covered Recipient Entity
Anmed Health
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis No dispute reported 06/30/2026 1235999003
Principal investigator 1 United Therapeutics Corporation $10,222.95 01/10/2025 Covered Recipient Teaching Hospital
Anmed Health
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242380226